Vendor, Gaithersburg, MD
Dexorgen Inc.
UEI ZNUMJ4FKRC19, CAGE 62JZ3
6 awards and $24,900 obligated between February 26, 2024 and February 6, 2026, 17% under full and open competition, against 1.0 offers on average where reported. 1 of the awards trace back to a SAM.gov solicitation on this site.
Industries
NAICS on the awards, by dollars.
| Testing Laboratories and ServicesNAICS 541380 | $36,540 |
| All Other Professional, Scientific, and Technical ServicesNAICS 541990 | $13,200 |
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $0 |
| Biological Product (except Diagnostic) ManufacturingNAICS 325414 | -$24,840 |
How it wins
Awards by competition, set-aside and type.
| Not Competed Under SAP | 3 |
| Not Competed | 2 |
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Purchase Order | 5 |
| Definitive Contract | 1 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- HTLV ENVELOPE PROTEIN PRODUCTION SERVICES (AMBIS 2225428)
National Institutes of Health, National Institutes of Health Niaid
PresolicitationNAICS 541380Bethesda, MDNOI-NIAID-24-2225428Awarded to Dexorgen Inc.
Posted Jun 10, 2024
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93024P00784Purchase Order, June 26, 2024, Not Competed Under SAP, 1 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | HTLV Envelope Protein Production Services (Ambis #2225428)NAICS 541380, PSC Q301 | $25,770 |
| 75N95024P00487Purchase Order, August 29, 2024, Not Competed Under SAP, 1 offers | National Institutes of Health NidaNational Institutes of Health | Generation and Characterization Ipsc Derived Brain Organoids from Bain Type X-Linked Mental Retardation Syndrome (Mrxsb)NAICS 541380, PSC Q301 | $24,000 |
| 75N95C25P00106Purchase Order, September 18, 2025, Not Competed Under SAP, 1 offers | National Institutes of Health NcatsNational Institutes of Health | Develop and Optimize Antagonists Assays in Acvr1-Wt, Acvr1-R206h,acvr1-T283i and Acvr1-R206h-T283i CellsNAICS 541990, PSC Q301 | $13,200 |
| 75N94019C00010Definitive Contract, February 26, 2024, Full and Open Competition After Exclusion of Sources, 1 offers | National Institutes of Health NichdNational Institutes of Health | EO14042 Development of Novel Pde4b Inhibitors to Treat Alcohol Use Disorder SBIR Phase IINAICS 541714, PSC AZ12 | $0 |
| 75N95020P00200Purchase Order, March 28, 2025, Not Competed, 1 offers | National Institutes of Health NidaNational Institutes of Health | Production of Recombinant Coronavirus Main Protease Enzymes.NAICS 541380, PSC Q301 | -$13,230 |
| 75N93021P01316Purchase Order, February 6, 2026, Not Competed, 1 offers | National Institutes of Health NiaidNational Institutes of Health | To Administratively De-Obligate Unexpended and Expiring Fiscal Year 2021 Funding in Accordance with 31 U.S.C. Section 1552 (A), in PreparatiNAICS 325414, PSC 6509 | -$24,840 |
- Places of performance
- Maryland
- Product and service codes
- Q301 Reference Laboratory TestingAZ12 6509 Drugs and Biologicals, Veterinary Use.
- Transactions
- 6 across 6 awards